{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:58Z","timestamp":1786985278908,"version":"build-2736575974"},"reference-count":113,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH108653"],"award-info":[{"award-number":["R01 MH108653"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["104631\/Z\/14\/Z"],"award-info":[{"award-number":["104631\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.biopsych.2018.01.014","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:14:20Z","timestamp":1517404460000},"page":"915-923","source":"Crossref","is-referenced-by-count":18,"title":["Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use\u00a0Disorders"],"prefix":"10.1016","volume":"83","author":[{"given":"Anthony G.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor W.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2018.01.014_bib1","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/S0140-6736(16)30655-9","article-title":"Time for mental health to come out of the shadows","volume":"387","author":"Kleinman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2018.01.014_bib2","article-title":"Making mental health a global priority","volume":"2016","author":"Marquez","year":"2016","journal-title":"Cerebrum"},{"key":"10.1016\/j.biopsych.2018.01.014_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2215-0366(15)00505-2","article-title":"Estimating the true global burden of mental illness","volume":"2","author":"Vigo","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrd4489","article-title":"Securing the future of drug discovery for central nervous system disorders","volume":"13","author":"Andersen","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.biopsych.2018.01.014_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu100","article-title":"Proceedings of the 2013 CINP Summit: Innovative partnerships to accelerate CNS drug discovery for improved patient care","volume":"18","author":"Phillips","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.biopsych.2018.01.014_bib6","first-page":"12","article-title":"The death of CNS drug development: Overstatement or omen?","volume":"3","author":"Riordan","year":"2011","journal-title":"J\u00a0Clin Studies"},{"key":"10.1016\/j.biopsych.2018.01.014_bib7","article-title":"The great neuro-pipeline \u2018brain drain\u2019 (and why big pharma hasn\u2019t given up on CNS disorders)","author":"Skripka-Serry","year":"2013","journal-title":"Drug Discovery World"},{"key":"10.1016\/j.biopsych.2018.01.014_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/scientificamerican0410-44","article-title":"Faulty circuits","volume":"302","author":"Insel","year":"2010","journal-title":"Sci Am"},{"key":"10.1016\/j.biopsych.2018.01.014_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1037\/h0040957","article-title":"Construct validity in psychological tests","volume":"52","author":"Cronbach","year":"1955","journal-title":"Psychol Bull"},{"key":"10.1016\/j.biopsych.2018.01.014_bib10","series-title":"Psychopharmacology: The Fourth Generation of Progress","first-page":"787","article-title":"Animal models of psychiatric disorders","author":"Geyer","year":"1995"},{"key":"10.1016\/j.biopsych.2018.01.014_bib11","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bcp.2010.12.028","article-title":"Translating cognition from animals to humans","volume":"81","author":"Keeler","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2013.03.022","article-title":"Innovative solutions to novel drug development in mental health","volume":"37","author":"Insel","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2018.01.014_bib13","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1111\/bph.13826","article-title":"Cross-species studies of cognition relevant to\u00a0drug discovery: A translational approach","volume":"174","author":"Robbins","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/npp.2008.173","article-title":"Removing obstacles in neuroscience drug discovery: The future path for animal models","volume":"34","author":"Markou","year":"2009","journal-title":"Neuropsychopharmacol Rev"},{"key":"10.1016\/j.biopsych.2018.01.014_bib15","unstructured":"Pizzagalli D (2016): Translational assessments of reward and anhedonia. Video presentation at the Athina Markou Memorial Symposium, November 10, San Diego, California. Available at: https:\/\/www.youtube.com\/watch?v=xE34C05Vm40&index=8&list=PLbbCsk7MUIGerbAPxOgCKsrZGdNksFo82. Accessed November 10, 2016."},{"key":"10.1016\/j.biopsych.2018.01.014_bib16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.neubiorev.2010.01.012","article-title":"Assessing cognitive function in clinical trials of schizophrenia","volume":"34","author":"Barnett","year":"2010","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2018.01.014_bib17","series-title":"Translational Neuropsychopharmacol","first-page":"450","article-title":"The Paired Associates Learning (PAL) Test: 30 years of CANTAB Translational Neuroscience From Laboratory to Bedside in Dementia Research","author":"Barnett","year":"2016"},{"key":"10.1016\/j.biopsych.2018.01.014_bib18","first-page":"266","article-title":"Cambridge Neuropsychological Test Automated Battery (CANTAB): A factor analytic study of a large sample of normal elderly volunteers","volume":"5","author":"Robbins","year":"1994","journal-title":"Dementia"},{"key":"10.1016\/j.biopsych.2018.01.014_bib19","series-title":"Psychobiological Foundations of Clinical Psychiatry","first-page":"1","article-title":"Animal models of psychopathology","author":"Segal","year":"1986"},{"key":"10.1016\/j.biopsych.2018.01.014_bib20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.1077141","article-title":"Medicine: What are the right targets for psychopharmacology?","volume":"299","author":"Hyman","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2018.01.014_bib21","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders","volume":"167","author":"Insel","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/10298420290023963","article-title":"Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across psychiatric diagnostic categories","volume":"4","author":"Markou","year":"2002","journal-title":"Neurotox Res"},{"key":"10.1016\/j.biopsych.2018.01.014_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.biopsych.2014.01.006","article-title":"A\u00a0neurodevelopmental perspective on the research domain criteria (RDoC) framework","volume":"76","author":"Casey","year":"2014","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jad.2016.12.011","article-title":"Research domain criteria (RDoC) grows up: Strengthening neurodevelopmental investigation within the RDoC framework","volume":"216","author":"Mittal","year":"2017","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.biopsych.2018.01.014_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S1461145703003973","article-title":"Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder","volume":"7","author":"Biederman","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00004583-200207000-00008","article-title":"Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial","volume":"41","author":"Kratochvilm","year":"2002","journal-title":"J\u00a0Am Acad Child Adol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1177\/0269881115602489","article-title":"Atomoxetine in patients with ADHD: a clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients","volume":"29","author":"Clemow","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrn.2017.8","article-title":"Fractionating impulsivity: Neuropsychiatric implications","volume":"18","author":"Dalley","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib29","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/j.biopsych.2011.02.036","article-title":"The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit hyperactivity disorder","volume":"69","author":"Del Campo","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0893-133X(02)00346-9","article-title":"Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit\/hyperactivity disorder","volume":"27","author":"Bymaster","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00213-002-1154-7","article-title":"The 5-choice serial reaction time task: Behavioral pharmacology and functional neurochemistry","volume":"163","author":"Robbins","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2018.01.014_bib32","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1126\/science.1137073","article-title":"Nucleus accumbens D2\/3 receptors predict trait impulsivity and cocaine reinforcement","volume":"315","author":"Dalley","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2018.01.014_bib33","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/npp.2013.44","article-title":"Baseline-dependent effects of cocaine pre-exposure on impulsivity and D(2\/3) receptor availability in the rat striatum: Possible relevance to the attention-deficit hyperactivity syndrome","volume":"38","author":"Caprioli","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib34","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1523\/JNEUROSCI.3890-14.2015","article-title":"Dissociable rate-dependent effects of oral methylphenidate on impulsivity and d2\/3 receptor availability in the striatum","volume":"35","author":"Caprioli","year":"2015","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib35","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.npp.1301487","article-title":"Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat","volume":"33","author":"Robinson","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib36","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/npp.2012.53","article-title":"Norepinephrine and dopamine modulate impulsivity on the five-choice serial reaction time task through opponent actions in the shell and core sub-regions of the nucleus accumbens","volume":"37","author":"Economidou","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1037\/a0035230","article-title":"On the ability to inhibit thought and action: general and special theories of an act of control","volume":"121","author":"Logan","year":"2014","journal-title":"Psychol Rev"},{"key":"10.1016\/j.biopsych.2018.01.014_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/A:1010329714819","article-title":"The ecological validity of delay aversion and response inhibition as measures of impulsivity in AD\/HD: A supplement to the NIMH multimodal treatment study of AD\/HD","volume":"29","author":"Solanto","year":"2001","journal-title":"J\u00a0Abnorm Child Psychol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib39","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1126\/science.1121218","article-title":"Neurochemical modulation of response inhibition and probabilistic learning in humans","volume":"311","author":"Chamberlain","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2018.01.014_bib40","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.biopsych.2007.03.003","article-title":"Atomoxetine improved response inhibition in adults with attention-deficit\/hyperactivity disorder","volume":"62","author":"Chamberlain","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.biopsych.2008.10.014","article-title":"Atomoxetine modulates right inferior frontal activation during inhibitory control: A pharmacological functional magnetic resonance imaging study","volume":"65","author":"Chamberlain","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib42","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nn.3092","article-title":"Adolescent impulsivity phenotypes characterized by distinct brain networks","volume":"15","author":"Whelan","year":"2012","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib43","doi-asserted-by":"crossref","first-page":"9254","DOI":"10.1523\/JNEUROSCI.1543-11.2011","article-title":"Prefrontal and monoaminergic contributions to stop-signal performance in rats","volume":"31","author":"Bari","year":"2011","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib44","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00213-017-4643-4","article-title":"Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals","volume":"234","author":"Passamonti","year":"2017","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2018.01.014_bib45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1126\/science.1214463","article-title":"Abnormal brain structure implicated in stimulant drug addiction","volume":"335","author":"Ersche","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2018.01.014_bib46","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/brain\/awu117","article-title":"Targeting impulsivity in Parkinson's disease using atomoxetine","volume":"137","author":"Kehagia","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2018.01.014_bib47","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.biopsych.2014.01.024","article-title":"Improving response inhibition in Parkinson\u2019s disease with atomoxetine","volume":"77","author":"Ye","year":"2015","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib48","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/npp.2016.18","article-title":"Atomoxetine enhances connectivity of prefrontal networks in Parkinson\u2019s disease","volume":"41","author":"Borchert","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/eb-2016-102355","article-title":"Ketamine for treatment resistant depression: Recent developments and clinical applications","volume":"19","author":"Schwartz","year":"2016","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.biopsych.2018.01.014_bib50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/da.22501","article-title":"Ketamine\u2019s mechanism of action: A path to rapid-acting antidepressants","volume":"33","author":"Abdallah","year":"2016","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.biopsych.2018.01.014_bib51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/2045125316631267","article-title":"Ketamine enantiomers in the rapid and sustained antidepressant effects","volume":"6","author":"Muller","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib52","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","article-title":"Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics","volume":"66","author":"Abdallah","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.biopsych.2018.01.014_bib53","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.drudis.2016.01.016","article-title":"Emerging treatment mechanisms for depression: Focus on glutamate and synaptic plasticity","volume":"21","author":"Gerhard","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.biopsych.2018.01.014_bib54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.apcsb.2015.10.003","article-title":"Glutamatergic NMDA receptor as therapeutic target for depression","volume":"103","author":"R\u00e9us","year":"2016","journal-title":"Adv Protein Chem Struct Biol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib55","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2018.01.014_bib57","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejphar.2012.11.023","article-title":"Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in alpha7 nicotinic acetylcholine receptors","volume":"698","author":"Moaddel","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib60","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib61","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1038\/npp.2014.123","article-title":"The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression","volume":"39","author":"Jim\u00e9nez-Sanchez","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib62","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s40473-015-0050-5","article-title":"Novel glutamatergic treatments for severe mood disorders","volume":"2","author":"Park","year":"2015","journal-title":"Curr Behav Neurosci Rep"},{"key":"10.1016\/j.biopsych.2018.01.014_bib63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbr.2014.05.065","article-title":"Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats","volume":"271","author":"Koike","year":"2014","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2018.01.014_bib64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1503\/jpn.160175","article-title":"Antidepressant effects of ketamine and of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism","volume":"42","author":"Alexandrova","year":"2017","journal-title":"J\u00a0Psychiatry Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib65","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/mp.2016.34","article-title":"Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects","volume":"22","author":"Chowdhury","year":"2016","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib66","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib67","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.euroneuro.2015.07.002","article-title":"Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat","volume":"25","author":"Bj\u00f6rkholm","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib68","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0269881115573809","article-title":"Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in\u00a0vivo electrophysiological study on monoaminergic and glutamatergic neurons","volume":"29","author":"El Iskandrani","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib69","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1523\/JNEUROSCI.4998-12.2013","article-title":"Acute suppression of spontaneous neurotransmission drives synaptic potentiation","volume":"33","author":"Nosyreva","year":"2013","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib70","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s00213-016-4399-2","article-title":"Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression","volume":"233","author":"Yang","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2018.01.014_bib71","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2018.01.014_bib72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuroscience.2012.03.052","article-title":"Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA\/NMDA receptor density ratio in female Wistar-Kyoto rats","volume":"213","author":"Tizabi","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2018.01.014_bib73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2011.05.035","article-title":"Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression","volume":"224","author":"Koike","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2018.01.014_bib74","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/sj.npp.1301312","article-title":"Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders","volume":"32","author":"Beneyto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1017\/S1461145712000016","article-title":"Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects","volume":"16","author":"Duric","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib76","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neubiorev.2015.03.005","article-title":"The role of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: Central mediators of pathophysiology and antidepressant activity?","volume":"52","author":"Freudenberg","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2018.01.014_bib77","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1471-4159.2008.05642.x","article-title":"Age-dependent effects of chronic stress on brain plasticity and depressive behavior","volume":"107","author":"Toth","year":"2008","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.biopsych.2018.01.014_bib78","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.npp.1301178","article-title":"The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders","volume":"32","author":"Du","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib79","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2018.01.014_bib80","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","article-title":"BDNF\u2014a key transducer of antidepressant effects","volume":"102","author":"Bj\u00f6rkholm","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib81","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neures.2005.06.008","article-title":"Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly","volume":"53","author":"Murakami","year":"2005","journal-title":"Neurosci Res"},{"key":"10.1016\/j.biopsych.2018.01.014_bib82","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/bcp.12845","article-title":"New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs","volume":"92","author":"Ign\u00e1cio","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib83","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eurpsy.2013.10.005","article-title":"Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex","volume":"29","author":"Zhou","year":"2014","journal-title":"Eur Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.biopsych.2018.01.014_bib84","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1590\/1516-4446-2013-1098","article-title":"Animal models as tools to study the pathophysiology of depression","volume":"35","author":"Abelaira","year":"2013","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.biopsych.2018.01.014_bib85","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2018.01.014_bib86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2012.12.009","article-title":"Sex differences in the antidepressant-like effects of ketamine","volume":"70","author":"Carrier","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib87","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bbr.2016.06.041","article-title":"Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice","volume":"312","author":"Thelen","year":"2016","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2018.01.014_bib88","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12094","article-title":"Ketamine for chronic pain: risks and benefits","volume":"77","author":"Niesters","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib89","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuropharm.2006.10.016","article-title":"Pharmacological profile of the \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid","volume":"52","author":"Rollema","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib90","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.tips.2007.05.003","article-title":"Rationale, pharmacology and clinical efficacy of partial agonists of \u03b14\u03b22 nAch receptors for smoking cessation","volume":"28","author":"Rollema","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib91","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1523\/JNEUROSCI.22-09-03338.2002","article-title":"Neuronal systems underlying behaviors related to nicotine addiction: Neural circuits and molecular genetics","volume":"22","author":"Picciotto","year":"2002","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib92","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/j.1460-9568.2007.05546.x","article-title":"Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell","volume":"25","author":"Paterson","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib93","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/syn.10242","article-title":"Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats","volume":"50","author":"Bruijnzeel","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2018.01.014_bib94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial","volume":"296","author":"Gonzales","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2018.01.014_bib95","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, vs place or sustained-release bupropion for smoking cessation: a randomized controlled trial","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2018.01.014_bib96","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bcp.2007.06.033","article-title":"Neuronal nicotinic receptors: a perspective on two decades of drug discovery research","volume":"74","author":"Arneric","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.biopsych.2018.01.014_bib97","unstructured":"Koob G (2016): Negative reinforcement mechanisms in drug addiction. Video presentation at the Athina Markou Memorial Symposium, November 10, San Diego, California. Available at: https:\/\/www.youtube.com\/watch?v=Lt8U6eQRAuU&index=2&list=PLbbCsk7MUIGerbAPxOgCKsrZGdNksFo82. Accessed November 10, 2016."},{"key":"10.1016\/j.biopsych.2018.01.014_bib98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tins.2011.11.005","article-title":"The neurobiology of anhedonia and other reward-related deficits","volume":"351","author":"Der-Avakian","year":"2012","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.biopsych.2018.01.014_bib99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biopsych.2006.03.053","article-title":"Metabotropic glutamate receptor antagonists: Novel therapeutics for nicotine dependence and depression?","volume":"61","author":"Markou","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib100","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jamapsychiatry.2014.1016","article-title":"Withdrawal of nicotine blunts reward responsiveness in humans and rats","volume":"71","author":"Pergadia","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib101","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.neuropharm.2013.05.042","article-title":"Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation","volume":"76B","author":"Li","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib102","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00213-016-4220-2","article-title":"Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats","volume":"233","author":"Li","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib103","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.biopsych.2018.02.006","article-title":"The gamma-aminobutyric acid B receptor in depression and reward","volume":"83","author":"Jacobson","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.014_bib104","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00213-010-2119-x","article-title":"Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats","volume":"215","author":"Vlachou","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib105","unstructured":"Cryan JF (2016): GABAB receptors as targets for treating psychiatric disorders. Video presentation at the Athina Markou Memorial Symposium, November 10, San Diego. Available at https:\/\/www.youtube.com\/watch?v=WJT5fTqhrAI&index=16&list=PLbbCsk7MUIGerbAPxOgCKsrZGdNksFo82. Accessed November 10, 2016."},{"key":"10.1016\/j.biopsych.2018.01.014_bib106","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/npp.2011.103","article-title":"The metabotropic glutamate 2\/3 receptor agonist LY379268 blocked nicotine-induced increases in nucleus accumbens shell dopamine only in the presence of a nicotine-associated context in rats","volume":"36","author":"D\u2019Souza","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.014_bib107","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00023210-200822090-00001","article-title":"Role of the glutamatergic system in nicotine dependence: Implications for the discovery and development of new pharmacological smoking cessation therapies","volume":"22","author":"Liechti","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2018.01.014_bib108","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1021\/jm3005306","article-title":"Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators structure-activity relationships and assessment in a rat model of nicotine dependence","volume":"55","author":"Sidique","year":"2012","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.biopsych.2018.01.014_bib109","unstructured":"Cross A (2016): Metabotropic glutamate receptors as targets for treating nicotine addiction. Video presentation at the Athina Markou Memorial Symposium, November 10, San Diego, California. Available at https:\/\/www.youtube.com\/watch?v=YFwvQFP_nxI&index=15&list=PLbbCsk7MUIGerbAPxOgCKsrZGdNksFo82. Accessed November 10, 2016."},{"key":"10.1016\/j.biopsych.2018.01.014_bib110","unstructured":"National Institute on Drug Abuse (2013): NIDA and AstraZeneca partner to develop potential addiction medication. May 10. Available at http:\/\/www.drugabuse.gov\/news-events\/news-releases\/2013\/05\/nida-astrazeneca-partner-to-develop-potential-addiction-medication. Accessed November 10, 2016."},{"issue":"9","key":"10.1016\/j.biopsych.2018.01.014_bib111","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant Schizophrenic: A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"76","key":"10.1016\/j.biopsych.2018.01.014_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002399","article-title":"The precompetitive space: Time to move the yardsticks","volume":"3","author":"Norman","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.biopsych.2018.01.014_bib113","article-title":"Reconfiguring drug discovery through innovative partnerships","author":"Grundy","year":"2014","journal-title":"Drug Discovery World"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322318300453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322318300453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T10:51:34Z","timestamp":1535107894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322318300453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":113,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0006322318300453"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2018.01.014","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}